^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CART-PSMA- TGFβRDN cells
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead
Drug class:
PSMA-targeted CAR-T immunotherapy, TGF-βRDN-targeted CAR-T immunotherapy
Related drugs:
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
04/26/2024
Initiation :
03/08/2017
Primary completion :
09/08/2038
Completion :
12/08/2038
TGFB1
|
FOLH1 expression
|
cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
Share
